AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02562443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
Study NCT02562443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any approved or standard-of-care therapy
Description: Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
Study NCT02562443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best supportive care (BSC)
Description: Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
Study NCT02562443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: best supportive care (BSC)
Description: Patients will receive best supportive care (BSC).
Study NCT04845204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Treatment
Description: Relaxation Group recieve progressive muscle relaxation exercises additional to the standard exercises. The relaxation exercises are applied two times a day till the discharge day starting on the postoperative day one. Progressive muscle relaxation included the relaxing of different muscle groups along with deep breathing. The maximal contraction period consist of the contraction of muscle groups around ankle, calf, knee, hip, lumbar, thoracic and cervical regions, shoulder, arm, forearm for 5 s and continued with a relaxation period for 30 s while focusing on breathing. These two periods ware repeated for each muscle groups and lasted approximately 30 min
Study NCT04845204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercises
Description: The physiotherapy protocol is applied under the supervision of the same physiotherapist within a progressive manner immediately after surgery. Continued passive range of motion is applied twice a day starting with 45º of knee flexion range of motion and increased gradually as tolerated. All patients performed same isometric, isotonic and active exercises. Patients were instructed to bear weight as tolerated on the postoperative day 1
Study NCT03330405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 1b
Description: Avelumab
Study NCT03330405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 1b
Description: Talazoparib
Study NCT03330405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
Study NCT03330405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
Study NCT04101253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new screening procedure with small variations in electrode positioning
Description: Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist.
Study NCT01638429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Neomycin: 500mg po bid for 10 days
Study NCT01638429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin: 550mg po tid for 10 days
Study NCT03823573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk within 24 hours
Description: Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
Study NCT03823573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk within 24 hours
Description: Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
Study NCT01194375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Strength IDP-107
Description: Once a day for 16 weeks
Study NCT01194375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-107
Description: Once a day for 16 weeks
Study NCT01194375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day for 16 weeks
Study NCT00588978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and/or exercise
Description: Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
Study NCT01828489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 1 mitoxantrone versus DaunoXome
Description: In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
Study NCT01828489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation course 1 mitoxantrone versus DaunoXome
Description: In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
Study NCT01828489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomisation course 2 ADxE versus FLADx
Description: The second course is randomised to either ADxE (standard arm) or FLADx
Study NCT01828489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation course 2 ADxE versus FLADx
Description: The second course is randomised to either ADxE (standard arm) or FLADx
Study NCT03293459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shunt Occlusion
Description: Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
Study NCT03293459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment (SMT)
Description: These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
Study NCT03293459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment (SMT)
Description: These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
Study NCT03064217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Making impression at surgery
Description: Making impression at surgery
Study NCT01503762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: mirror therapy
Study NCT01503762 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Classical rehabilitation techniques
Description: splinting, tendon gliding, active range of motion, activities of daliy living
Study NCT02597244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Extraforaminotomy
Description: percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
Study NCT04129164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VIB4920
Description: Intravenous Dose 1.
Study NCT04129164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Intravenous Dose 1.
Study NCT04129164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: diclofenac
Description: Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
Study NCT04129164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.
Study NCT01316575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCPAP
Description: The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
Study NCT01316575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Oxygen
Description: The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
Study NCT01869504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon-tipped intercostal drain
Description: Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
Study NCT00827476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian transplantation
Description: ovarian xenotransplantation or in vitro culture
Study NCT00734357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood work
Description: Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
Study NCT01056497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
Study NCT01514708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S Influenza Vaccine
Description: Suspension for injection
Study NCT01738659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal sodium diet
Description: normal sodium diet (120 mmol/daily) for 1 year
Study NCT03856190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting and plant-based nutrition
Description: The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
Study NCT03856190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Counselling
Description: The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
Study NCT03517813 — intervention group
Intervention type: DEVICE
Intervention: Contrast-enhanced Spectral Mammography (CESM)
Description: Dual energy mammography images obtained after the administration of an intravenous contrast agent
Study NCT03377699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
Study NCT03377699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
Study NCT03377699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
Study NCT03377699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
Study NCT00224887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In home nutrition counseling
Description: In home family-based behavioral counseling
Study NCT00224887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard nutrition education curriculum
Description: video and lesson plans based on USDA Food Guide Pyramid
Study NCT02672852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection
Study NCT02672852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection
Study NCT03384160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 -Pain monitor
Description: Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
Study NCT03384160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 -Pain monitor
Description: Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
Study NCT01609244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)
Description: nighttime positive airway therapy for 6 weeks
Study NCT01609244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)
Description: nighttime positive airway therapy for 6 weeks
Study NCT03476759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal adhesiolysis
Description: 125 patients will undergo tubal adhesiolysis or tuboplasty
Study NCT03476759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: 125 patients will undergo IVF-ICSI procedures.
Study NCT03625180 — intervention group
Intervention type: BIOLOGICAL
Intervention: NAMIC: nanofractured autologous matrix-induced chondrogenesis
Description: the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
Study NCT03712059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT test and colonoscopy
Description: All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
Study NCT03712059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polypectomy and biopsy
Description: All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
Study NCT03712059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Classification
Description: Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
Study NCT00541242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% eye drops
Description: Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
Study NCT00541242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% eye drops
Description: Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
Study NCT02203266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
Study NCT02203266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
Study NCT02577536 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions will be conducted under this study.
Study NCT03669588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: Intravenous administration of ARGX-113
Study NCT03669588 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo
Study NCT03907644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
Study NCT03907644 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
Study NCT02157389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of a pharmacological placebo
Study NCT02725021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco school-based intervention by medical students
Study NCT04546425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine
Study NCT04546425 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study NCT00564746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
Description: \[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed.
Study NCT01461811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A toric contact lenses (with comfort additives)
Study NCT01461811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A toric contact lenses
Study NCT03865927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: see Arm/Group description
Study NCT03865927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: GKT137831 is a NOX enzyme inhibitor
Study NCT04116892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Cover group
Description: The internal limiting membrane around the MH was left to cover the hole
Study NCT00953030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH
Study NCT00953030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealAge
Study NCT04105179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer NexGen LPS-Flex
Description: Patients will be randomly assigned to 1 of 2 devices
Study NCT04105179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Journey II
Description: Patients will be randomly assigned to 1 of 2 devices
Study NCT02460016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 pellets for oral administration
Study NCT03905733 — intervention group
Intervention type: DEVICE
Intervention: Optiflow
Description: supply of oxygen at 2 L / min/ kg through Optiflow